Could good intentions lead to future danger?

The global COVID-19 pandemic has put the pharma/biopharma industry in the headlines on a daily basis. Many people compare the COVID-19 pandemic to the Spanish influenza epidemic of 1918. However, aside from their being different diseases, a major difference is the ability of the modern industry to develop and share tests and treatments with unprecedented speed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Teva faces scrutiny over efforts to curb generic competition

27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

More features

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Tempus AI bid to derail DNA patent case hits snag

Teva faces scrutiny over efforts to curb generic competition

FDA targets faster generic approvals in drive to slash drug prices

China-origin biotech assets and the hidden question of IP ownership

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

Could good intentions lead to future danger?

More on this story

Editor's picks

Editor's picks

More features